Hoe verhoudt ZYNE's PB Ratio zich tot zijn concurrenten?

ZYNE is een goede waarde op basis van zijn Price-To-Book Ratio (2.3x) vergeleken met het gemiddelde van gelijken (16.4x).

Hoe verhoudt ZYNE's PB Ratio zich tot andere bedrijven in de US Pharmaceuticals industrie?

ZYNE is duur op basis van de Price-To-Book -ratio ( 2.3 x) vergeleken met het US Pharmaceuticals -industriegemiddelde ( 1.6 x).

Wat is ZYNE's PB Ratio vergeleken met zijn Fair PB Ratio? Dit is de verwachte PB Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Book Fair Ratio van { ZYNE te berekenen voor waarderinganalyse.

Wat is de reële prijs van ZYNE als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

ZYNE ( $1.3 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( $53.8 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling is lager dan de huidige aandelenkoers.

Zynerba Pharmaceuticals (Nasdaq:ZYNE) - Aandelenkoers, Nieuws & Analyse

ZYNE Overzicht aandelen

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company.

Over het bedrijf

ZYNE fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 97.6% onder onze schatting van de reële waarde

De winst zal naar verwachting met 67.21% per jaar groeien

De winst is de afgelopen 5 jaar met 0.8% per jaar gegroeid

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Heeft minder dan 1 jaar cash runway

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft geen betekenisvolle marktkapitalisatie ( $66M )

+ 2 meer risico's

Zynerba Pharmaceuticals, Inc. Concurrenten

Nutriband

NasdaqCM:NTRB

US$62.7m

Citius Pharmaceuticals

NasdaqCM:CTXR

US$62.7m

MariMed

OTCPK:MRMD

US$57.3m

Landos Biopharma

NasdaqCM:LABP

US$71.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Zynerba Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$1.30
52 Week Hoogtepunt	US$1.40
52 Week Laag	US$0.25
Bèta	1.19
11 maand verandering	-1.52%
3 maanden verandering	282.24%
1 Jaar Verandering	96.08%
33 jaar verandering	-65.79%
5 jaar verandering	-82.17%
Verandering sinds IPO	-92.00%

Recent nieuws en updates

Recent updates

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Mar 01

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 11

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Oct 06

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

Aug 10

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Jul 22

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Jul 21

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Mar 23

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Dec 02

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

May 27

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Dec 17

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 23

Zynerba Pharmaceuticals EPS beats by $0.12

Nov 09

Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback

Oct 29

Rendement voor aandeelhouders

	ZYNE	US Pharmaceuticals	US Markt
7D	4.0%	-4.5%	2.3%
1Y	96.1%	10.9%	35.1%

Rendement versus industrie: ZYNE overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 10.9 % opleverde.

Rendement versus markt: ZYNE overtrof de US markt, die het afgelopen jaar een rendement opleverde van 35.1 %.

Prijsvolatiliteit

Is ZYNE's price volatile compared to industry and market?
ZYNE volatility
ZYNE Average Weekly Movement	84.2%
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van ZYNE is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van ZYNE is het afgelopen jaar gestegen van 43% naar 84%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	26	Armando Anido	www.zynerba.com

Zynerba Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Zynerba Pharmaceuticals zich tot de beurswaarde?
ZYNE fundamentele statistieken
Marktkapitalisatie	US$65.60m
Inkomsten(TTM)	-US$37.58m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.7x

Koers/Winstverhouding

Is ZYNE overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ZYNE resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$37.58m
Inkomsten	-US$37.58m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.74
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ZYNE op de lange termijn?

Bekijk historische prestaties en vergelijking

ZYNE Overzicht aandelen

Beloningen

Risicoanalyse

Zynerba Pharmaceuticals, Inc. Concurrenten

NasdaqCM:NTRB

US$62.7m

NasdaqCM:CTXR

US$62.7m

OTCPK:MRMD

US$57.3m

NasdaqCM:LABP

US$71.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

Recent updates

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

Price target decreased by 78% to US$1.26

New minor risk - Profitability

Zynerba Pharmaceuticals Provides Nasdaq Compliance Update

New major risk - Financial position

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Price target increased by 7.9% to US$5.80

Forecast to breakeven in 2025

Price target increased by 30% to US$7.00

Zynerba Pharmaceuticals Gets an Additional 180 Calendar Day Period, or Until October 30, 2023 to Regain Compliance with the Bid Price Rule

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$5.44

Zynerba Pharmaceuticals Announces Update on Reconnect, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the Annual Meeting of the American College of Neuropsychopharmacology

Zynerba Pharmaceuticals, Inc. Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel(TM) in the Journal of Neurodevelopmental Disorders

Price target increased to US$8.33

Insufficient new directors

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba Pharmaceuticals Receives a Deficiency Letter from Nasdaq

Zynerba Pharmaceuticals, Inc. Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the National Organization for Rare Disorders (Nord) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome At the International Society for Autism Research Annual Meeting

Price target decreased to US$6.95

Insufficient new directors

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Price target decreased to US$6.95

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces European Commission Grants Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Announces Executive Changes

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Pomerantz LLP and The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement Against Zynerba Pharmaceuticals, Inc

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Zynerba Pharmaceuticals, Inc. Receives Guidance from the U.S. Food and Drug Administration on Confirmatory Phase 3 Trial of Zygel in Patients with Fragile X Syndrome

New 90-day high: US$5.08

New 90-day low: US$3.27

Zynerba Pharmaceuticals, Inc. Provides Regulatory Update on Zygel™ in Fragile X Syndrome

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

New 90-day high: US$3.88

Zynerba Pharmaceuticals EPS beats by $0.12